5 Stocks to Buy According to Stephen DuBois’ Camber Capital Management

3. Sanofi (NASDAQ:SNY)

Camber Capital Management’s Stake Value: $205,360,000
Percentage of Camber Capital Management’s Portfolio: 7.42%
Number of Hedge Fund Holders: 19

Sanofi (NASDAQ:SNY) is a global French healthcare corporation headquartered in Paris, France. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on July 1 that it had successfully acquired Sanofi (NASDAQ:SNY)’s interest in Libtayo. As a result, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) would own the exclusive rights to produce the medicine that was first created in Regeneron’s research labs and commercialize it globally.

On June 7, UBS analyst Laura Sutcliffe maintained a ‘Buy’ recommendation on Sanofi (NASDAQ:SNY), while increasing her price objective to EUR 119 from EUR 118. In addition, Camber Capital Management elevated its position in Sanofi (NASDAQ:SNY) by 6% in Q1 2022, holding 4 million shares worth over $205 million. The stock accounted for 7.42% of the fund’s total 13F portfolio.

According to Insider Monkey’s database, 19 hedge funds had a stake in Sanofi (NASDAQ:SNY) as of Q1 2022, with the total value of their holdings standing at $1.57 billion. Ken Fisher’s Fisher Asset Management held the most significant stake in Sanofi (NASDAQ:SNY) at the end of the first quarter of 2022, valued at $920.67 million.

Here’s what Dodge & Cox Stock Fund said about Sanofi (NASDAQ:SNY) in its Q3 2021 investor letter:

“Sanofi (3.5% position) is a diversified, global pharmaceuticals company with leading positions in vaccines, consumer health products, rare diseases, and emerging markets. Despite a favorable business mix, Sanofi has underperformed its peers in new product development, commercial execution, and profit growth. A new management team, recruited in 2018-19, has made progress turning the company around. Its drug pipeline is improving, targets for higher margins are being met, and earnings per share are growing. Sanofi also pays a 4% dividend yield, maintains a strong balance sheet, and has relatively low exposure to potential pressures from U.S. drug pricing.”